- Conditions
- Atopic Dermatitis
- Interventions
- Rocatinlimab Prefilled Syringe, Rocatinlimab AI
- Combination Product
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 100 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 22
- States / cities
- Bakersfield, California • Long Beach, California • Los Angeles, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 17,835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dengue Fever
- Interventions
- TDV
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- Psoriatic Arthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 18 more
- Conditions
- Hodgkin's Disease
- Interventions
- Nivolumab, Brentuximab vedotin
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 20
- States / cities
- Duarte, California • Long Beach, California • Los Angeles, California + 16 more
- Conditions
- Healthy
- Interventions
- Asacol, Lialda
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Dermatomyositis
- Interventions
- Brepocitinib, Placebo
- Drug
- Lead sponsor
- Priovant Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 33 more
- Conditions
- Solid Tumors
- Interventions
- Nilotinib + Paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years to 120 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Attention-Deficit/Hyperactivity Disorder
- Interventions
- extended-release guanfacine hydrochloride (SPD503), placebo, extended-release guanfacine hydrochloride
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • El Centro, California • Rolling Hills Estates, California + 38 more
- Conditions
- Multiple Myeloma
- Interventions
- Total Skeletal Irradiation
- Radiation
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Parkinson's Disease
- Interventions
- RO7046015, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 316 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2031
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- bevacizumab, erlotinib HCl, placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 4
- States / cities
- Vallejo, California • Athens, Georgia • Kansas City, Kansas + 1 more
- Conditions
- Myocarditis Acute, Cancer
- Interventions
- Abatacept plus, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 29
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 21 more
- Conditions
- Hemophilia B
- Interventions
- rIX-FP
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- Up to 70 Years · Male only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Indianapolis, Indiana • Philadelphia, Pennsylvania + 1 more
- Conditions
- Leukemia
- Interventions
- Arsenic Trioxide
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Head and Neck Cancer
- Interventions
- ADP-A2M4 in combination with pembrolizumab.
- Genetic
- Lead sponsor
- Adaptimmune
- Industry
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • San Diego, California • Kansas City, Kansas + 5 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Interventions
- Taletrectinib, Placebo
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- 89Zr-DFO-YS5, YS5 antibody, Positron Emission Tomography (PET)/Computerized tomography (CT), Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI)
- Drug · Biological · Procedure
- Lead sponsor
- Robert Flavell, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Weight Management
- Interventions
- ASC36 tablets, for oral use, ASC36 placebo tablets
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Renal Cell Carcinoma, Kidney Cancer
- Interventions
- Durvalumab, Tremelimumab
- Drug
- Lead sponsor
- Moshe Ornstein
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Cleveland, Ohio
- Conditions
- Healthy
- Interventions
- Pirtobrutinib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Hepatic Impairment, Cirrhosis
- Interventions
- VIR-2218, VIR-3434
- Drug
- Lead sponsor
- Vir Biotechnology, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 4
- States / cities
- Rialto, California • Tustin, California • Miami Lakes, Florida + 1 more
- Conditions
- Schizophrenia
- Interventions
- Xanomeline and Trospium Chloride Capsules, Placebo Capsules
- Drug
- Lead sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 182 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Lemon Grove, California • Long Beach, California + 9 more
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma, Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage III, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
- Interventions
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC, Physician's Choice of Immune Checkpoint Inhibitor: pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, Docetaxel
- Biological · Drug
- Lead sponsor
- Genelux Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Bullhead City, Arizona • Clermont, Florida • Coral Springs, Florida + 11 more
- Conditions
- Schizophrenia, Schizo Affective Disorder
- Interventions
- D-serine, Placebo
- Drug
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 2
- States / cities
- New York, New York • Orangeburg, New York